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1242 The Journal of Thoracic and CardObjectives: Cyclooxygenase-2 plays a role in growth, apoptosis, angiogenesis, and
metastasis in lung cancer. Inhibition of cyclooxygenase-2 with celecoxib has been
shown to inhibit tumor growth. We evaluated the effect of increasing doses of
celecoxib in a murine model of human lung cancer.
Methods: Human lung adenocarcinoma cells (A549) were implanted in the left lung
upper lobe of mice with severe combined immunodeficiency syndrome. Mice were
randomly assigned to 4 groups at implantation (n  10 per group): control, 125 mg/kg
chow, 500 mg/kg chow, 1000 mg/kg chow. After 3 weeks, mice were killed, and a
blinded observer measured total tumor volume. The dose effect of celecoxib was
examined in vitro by studying cell proliferation, expression of cyclooxygenase-2
(mRNA and protein), and production of prostaglandin E2 in unstimulated and interleu-
kin 1–stimulated cells.
Results: All 40 mice survived for 3 weeks with no observed toxicities. Total tumor
volume was inhibited in each celecoxib group (P  .0038, Welch analysis of
variance): 206.7  119.5 mm3 (control group), 41.4  54.0 mm3 (low-dose group),
34.5  39.3 mm3 (medium-dose group), and 27.3  53.6 mm3 (high-dose group).
In vitro celecoxib was effective at inhibiting production of prostaglandin E2, even
in stimulated cells, although little effect was seen on cyclooxygenase-2 protein
levels. Inhibition of proliferation was evident only at doses that exceeded those used
in the animal model.
Conclusion: Inhibition of cyclooxygenase-2 with low-dose celecoxib restricted the
growth of lung cancer in this model. This might be mediated by prostaglandin E2.
Higher doses of celecoxib afforded no additional benefit. Chronic therapy with
low-dose cyclooxygenase-2 inhibition has the potential to influence tumor progres-
sion in non–small cell lung cancer.
Cyclooxygenase-2 (COX-2) has been implicated as an important factor inmany epithelial tumors, including non–small cell lung cancer (NSCLC),in which expression of the enzyme is present in more than 70% of
cases.1-5 Cox-2 has been shown to affect many aspects of tumor development,
including angiogenesis, growth, invasion, and apoptosis.6-8 In addition, COX-2
is thought to promote metastatic behavior, although the mechanisms responsible
are not defined.9
We have previously shown that selective COX-2 inhibition with celecoxib
markedly decreased tumor growth and mediastinal metastases of a human lung
cancer cell line in an orthotopic mouse model.10 Evidence from other in vivo models
with lung cancer cell lines suggests that higher doses of celecoxib further suppress
tumors.11-14 This study was performed to assess whether selective COX-2 inhibition
has a dose-dependent effect on orthotopic NSCLC tumor growth by use of a
well-studied lung adenocarcinoma cell line, A549.
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The University of Southern California Institutional Animal Care
and Use Committee approved this animal study. All animals re-
ceived humane care in compliance with the “Guide for the Care
and Use of Laboratory Animals” published by the National Insti-
tutes of Health.
Cell Culture
Cells of the human lung adenocarcinoma cell line A549 (American
Type Culture Collection, Manassas, Va) were cultured in RPMI-1640
supplemented with 5% fetal bovine serum (GIBCO, Carlsbad, Calif),
2 mmol/L glutamine, 100 U/mL penicillin, and 100 g/mL strepto-
mycin at 37°C in a 5% CO2 humidified atmosphere. Cells were grown
to confluence and prepared for the following experiments.
In vivo model. Six-week old mice with severe combined im-
munodeficiency syndrome (SCID-bg male mice; Harlan Sprague
Dawley, Inc, Indianapolis, Ind) were housed in polycarbonate
cages (5 per cage) in a room lit for 12 hours each day and
maintained at 27°C for 2 days before injection. Teklad (4%) diet
(Harlan Teklad, Madison, Wis) and tap water were provided ad
libitum. Treatment diet consisted of Teklad (4%) mixed with
celecoxib at 125 mg/kg chow (low dose), 500 mg/kg chow (me-
dium dose), and 1000 mg/kg chow (high dose). Mice were ran-
domly assigned to 4 groups at implantation (n  10 per group):
control, low-dose, medium-dose, and high-dose groups. Celecoxib
administration began on the day of tumor cell implantation and
continued for 21 days.
In preparation for injection, A549 cells were resuspended to a
concentration of 2  106 cells per 25 L in PBS. Cell viability was
greater than 94% (trypan blue stain) before and after the procedure.
Mice were anesthetized by titrating isoflurane inhalant. A 1-cm axil-
lary incision allowed left lung visualization through the intercostal
muscles and pleura. A549 cell suspension was injected through a
27-gauge needle into the left upper lobe at the fourth intercostal space
under direct visualization. The incision was closed with 4-0 absorb-
able sutures, and mice were allowed to recover. Mice were arbitrarily
selected and killed at 3 weeks after implantation. At necropsy, a
blinded observer assessed the presence of mediastinal lymph nodes
and measured tumor volume (length  width  height) with digital
calipers. Tumors were either snap frozen in Tissue-Tek O.C.T. (Op-
timal Cutting Temperature) compound (Miles, Elkhart, Ind) in a
beaker of 2-isopropanol on dry ice (18°C) or fixed in 10% neutral
buffered formalin and embedded in paraffin.
Immunohistochemistry. Paraffin-embedded tissue sections
were prepared on poly-L-lysine–coated slides at 4 m. Sections
were dewaxed in xylene and rehydrated in graded alcohol baths.
Endogenous peroxidase was then blocked by means of incubation
in 3% H2O2 in methanol. Nonspecific mouse antigen was blocked
with BEATTM blocking reagent (Zymed, South San Francisco,
Calif). Primary antibody COX-2 (Cayman Chemical, Ann Arbor,
Mich) was applied at 1:100 dilution in primary antibody diluting
buffer (Biomedia, Foster City, Calif) at 4°C overnight. Detection
was through a horseradish peroxidase–conjugated anti-rabbit sec-
ondary antibody (Histomouse Max Kit, Zymed) and a DAB
chromagen (Zymed). Slides were counterstained with hematoxylin
(Vector, Burlingame, Calif). Normal rabbit serum diluted to the
same concentration as the primary and/or diluting buffer was used
as a negative control. Sections of human distal vas deferens were
The Journal of Thoracicused for positive controls. Sections were again dehydrated in
graded alcohol and placed under cover slips. Images were viewed
with an Olympus BX60 microscope and captured with a cooled
charge-coupled device camera (Magnafire; Olympus, Melville,
NY). Images were imported into Adobe Photoshop (Adobe Sys-
tems, Mountain View, Calif) as TIFF files.
Cell proliferation assays. The effect of COX-2 inhibition on
A549 cell growth was determined by using a cell proliferation assay.
For cell proliferation, A549 cells were seeded at a density of 5 103
per well in 96-well plates in RPMI-1640 with 10% fetal bovine serum
at 37°C. After 24 and 48 hours, fresh media with or without celecoxib
in 1% dimethyl sulfoxide (DMSO) was added. At 24, 48, and 72
hours, MTS (a novel tetrazolium compound) CellTiter 96 (Promega,
Madison, Wis) cell proliferation assay was performed. Viable cells
convert MTS into an aqueous formazan product, which was measured
on the basis of absorbance at 490 nm.
For cell counting, A549 cells were seeded at a density of 1 
106 cells per well in 12-well plates. Cells were treated with or
without celecoxib in DMSO for 24 hours. Floating and adherent
cells were combined; viable and total cell numbers were deter-
mined by use of trypan blue and a hemocytometer.
Western blot hybridization. A549 cells were seeded at a den-
sity of 1  106 cells per well in 12-well plates with 5% fetal
bovine serum and RPMI-1640 and incubated at 37°C overnight.
Cells were then washed in PBS and subjected to the following
treatments for 24 hours: media alone; 1% DMSO; 10 mol/L
celecoxib; interleukin (IL) 1 (1 ng/mL; PeproTech, Rocky Hill,
NJ); IL-1 plus 10 mol/L celecoxib; and IL-1 plus 50 mol/L
celecoxib. IL-1 was used to stimulate cells to produce COX-2.
Cell pellets were lysed for protein and RNA (see below). Protein
assay was performed by using the Bio-Rad DC protein assay kit
(Bio-Rad, Hercules, Calif). Samples were mixed with equal vol-
umes of Tris-Glycine SDS loading buffer (Invitrogen, Carlsbad,
Calif), heated at 90°C for 2 minutes, and loaded onto 8% to 16%
Tris-Glycine gels (Invitrogen). Proteins were resolved by means of
sodium dodecylsulfate–polyacrylamide gel electrophoresis (125 V
constant, 90 minutes, Tris-Glycine running buffer) and transferred
onto polyvinylidene difluoride membranes (25 V constant, 90
minutes, Tris-Glysine transfer buffer). Membranes were washed
and blocked overnight at 4°C with 5% nonfat dry milk in Tris-
buffered saline with 0.1% Tween at pH 7.5. Rabbit anti-human
COX-2 (Cayman) at 1:1000, and -actin at 1:800 (Santa Cruz,
Santa Cruz, Calif) antibody was applied for 1 hour at 37°C. After
washing, blots were incubated with horseradish peroxidase–linked
anti-rabbit IgG conjugates (Amersham Pharmacia, Arlington
Heights, Ill) at 1:1000 for 1 hour at room temperature. Antibody
complexes were visualized by means of enhanced chemilumines-
cence (Amersham). Blots were scanned with Flourochem 8900
(Alpha Innotech, San Leandro, Calif), AlphaEase imaging soft-
ware (version 5.0), and Adobe Photoshop 6.0.
Reverse transcriptase polymerase chain reaction. Total RNA
was extracted from A549 cells by using the RNeasy Mini-Kit
(Qiagen, Valencia, Calif), and then RNA quantity and purity were
confirmed spectrophotometrically. Reverse transcription was per-
formed with the GeneAmp RNA PCR reagent kit (Applied Bio-
systems, Foster City, Calif). We used 1 g of RNA normalized
from each sample; added 1 L of Oligo d(T) primer, 1 L of
MuLV reverse transcriptase, 1 L of RNase inhibitor, 2 L of 25
and Cardiovascular Surgery ● Volume 129, Number 6 1243
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ase chain reaction (PCR) buffer II with a total of 20 L of reaction
volume; incubated at 42°C for 30 minutes; heated at 99°C for 5
minutes; and cooled at 5°C for 5 minutes. Two microliters of
cDNA from reverse transcription was further used for PCR am-
plification, with 2.5 L of 10 PCR Buffer, 2.5 L of 25 mmol/L
MgCl2, 2 L of 2.5 mmol/L deoxyribonucleoside triphosphate, 0.2
L of Taq DNA polymerase, 2 L of primer, and RNase DNase-
free water to a 25-L reaction volume. The following primer
sequences were used: -actin, 5=-GAG CGG GAA ATC GTG
CGT GAC ATT-3= and 5=-GAT GGA GTT GAA GGT AGT TTC
GTG-3= (234 bp); COX-2, 5=-TGA AAC CCA CTC CAA ACA
CAG-3= and 5=-TCA TCA GGC ACA GGA GGA AG-3= (232 bp).
PCR was performed (PCR Express; Thermo Hybaid, Cambridge,
United Kingdom), with 35 cycles of denaturation at 94°C for 45
seconds, annealing at 55°C for 45 seconds, and extension at 72°C
for 1 minute. PCR products (10 L) were subjected to electro-
phoresis on 1.5% agarose gels and visualized by means of staining
with ethidium bromide.
Prostaglandin E2 Levels
Supernatant from the above experiments was collected and stored
at 70°C. Prostaglandin E2 (PGE2) concentration was determined
by using the Prostaglandin E2 Express ELISA immunoassay kit
(Cayman) according to the manufacturer’s instructions.
Statistics
Data are expressed as means  SD unless otherwise indicated.
Differences between means for in vivo experiments were evalu-
ated by using Welch analysis of variance (ANOVA) and ANOVA
with Bonferroni post-hoc analysis. For in vitro experiments, a
one-way ANOVA with Bonferroni post-test analysis was applied
where appropriate.
Results
Celecoxib Inhibits A549 Tumor Volume in an
Orthotopic Model
All 40 mice survived for 3 weeks without observed toxicity
Figure 1. Mouse with severe combined immunodeficiency syn-
drome bearing A549 orthotopic tumor and metastases at 21 days.
Asterisk, Primary tumor; arrowheads, metastases.as manifested by weight loss or change in behavior. At 3
1244 The Journal of Thoracic and Cardiovascular Surgery ● Junweeks after injection, left lung primary tumors and metas-
tases were apparent (Figure 1). Total tumor volume was
significantly inhibited in all treatment groups (P  .0038,
Welch ANOVA), and no dose-dependent effect was evident
(P  .05, ANOVA with Bonferroni post-hoc analysis; Fig-
ure 2). Total tumor volume was 206.7  119.5 mm3 in the
control group, 41.4 54.0 mm3 in the low-dose group, 34.5
 39.3 mm3 in the medium-dose group, and 27.31  53.6
mm3 in the high-dose group. Observed metastases were
fewer in all treatment arms. The mean number of metastases
was 22  15 in the control group and 10  9.5, 9.5  7.3,
and 11  9.5 for the low-, medium-, and high-dose groups,
respectively. No side effects of celecoxib were noted in any
of the treatment animals.
Orthotopic A549 Tumors Express COX-2
Tumors from all treatment groups were evaluated with
COX-2 immunohistochemistry. COX-2 antigen was de-
tected in orthotopic tumors both in the untreated animals
and in all treatment groups. COX-2 staining was evident in
the cytoplasm and nuclei of positive cells (Figure 3).
Dose-dependent Inhibition of A549 Proliferation In
Vitro
When A549 cells grown in culture were treated with in-
creasing doses of a COX-2 inhibitor, a dose-dependent
inhibition of proliferation was evident at 24, 48, and 72
hours, as demonstrated with an MTS proliferation assay
(Figure 4). At doses from 5 to 25 mol/L celecoxib, no
significant inhibition was evident (P  .05, ANOVA).
A549 Cells Express COX-2 and Produce PGE2
A549 cells in cell culture express low levels of COX-2, as
Figure 2. Orthotopic A549 versus celecoxib: absence of a dose-
dependent effect. Treatment with all doses of celecoxib resulted
in significant inhibition of total tumor volume (in cubic millime-
ters). **P  .0038, Welch ANOVA.determined by means of Western blotting and reverse tran-
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the inflammatory cytokine IL-1, large amounts of COX-2
protein and mRNA are induced (Figure 5, A). A concomi-
tant increase in PGE2 is evident in IL-1–stimulated cells.
When treated with 10 and 50 mol/L celecoxib, these
stimulated cells produce little PGE2. We found these same
cells to have less COX-2 mRNA than the cells stimulated
with IL-1 alone but similar amounts of protein (Figure 5,
B). In addition, there was a trend toward greater COX-2
protein expression in cells treated with IL-1 plus 50
mol/L celecoxib.
Discussion
The role of COX-2 in cancer has been studied extensively
since epidemiologic evidence implicated aspirin and non-
steroidal anti-inflammatory drugs (NSAIDs) in improved
colon carcinoma survival.15-17 COX-2, an inducible en-
Figure 3. A, Specific COX-2 immunostaining is evid
magnification 100.) COX-2 is present in the cytoplasm
demonstrate COX-2 expression. B, Negative control. (Ozyme, is upregulated in inflammatory processes and present
The Journal of Thoracicin many cancers; COX-1 is constitutive and responsible for
cellular homeostasis in many systems.18 Both enzymes con-
vert arachidonic acid into prostanoids. Although most
NSAIDS block both COX-1 and COX-2 activity, specific
COX-2 inhibitors, such as celecoxib, inhibit only the induc-
ible isoform. This explains the improved side-effect profile
of selective COX-2 inhibitors.
Several lines of in vivo evidence suggest that selective
and nonselective COX-2 inhibitors can attenuate lung can-
cer. Aspirin, sulindac, and NS398 (a selective COX-2 in-
hibitor) reduced lung cancer incidence in a dose-response
manner in mice exposed to tobacco-specific nitrosamine
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.19,20 Indo-
methacin inhibited the accumulation of tumor cells in
mouse lungs and the subsequent growth of lung metastases
after intravenous injection.21 Celecoxib dose dependently
inhibited primary tumor growth and the number and size of
in this section of orthotopic A549 tumor. (Original
d nucleus. Tumor sections from each treatment group
al magnification 100.)ent
an
riginlung metastases in Lewis lung carcinoma cells and human
and Cardiovascular Surgery ● Volume 129, Number 6 1245
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preferential COX-2 inhibitor, inhibited PGE2 production
and the growth of NSCLC cell lines.13
In this study an orthotopic mouse model of implanted
human lung adenocarcinoma cells was used to assess the
effect of 3 doses of celecoxib on tumor growth and metas-
tasis. The A549 adenocarcinoma cell line was chosen be-
cause it is well studied and previously demonstrated induc-
ible COX-2 expression.22,23 At 21 days after orthotopic
implantation, A549 tumors are well established, most with
evidence of mediastinal disease. This is consistent with our
experience with another COX-2–expressing lung adenocar-
cinoma cell line, NCI-1975, and with that of Onn and
colleagues.10,24
The celecoxib doses chosen for the in vivo study were
based on the literature and previous experience. The low
dose (125 mg/kg chow, equivalent to 25 mg/kg body weight
per day) was based on previously reported work that yielded
celecoxib plasma levels of 0.25 g/mL (0.6 mol/L).10
These levels are similar to the 0.2 g/mL (0.5 mol/L)
reported by Masferrer and associates12 in their Lewis lung
cancer mouse model. Similarly, the review by Davies and
coworkers25 of celecoxib pharmacokinetics reports that
adults taking 800 mg daily have plasma levels of 2.8 g/mL
(7.3 mol/L). The plasma levels of celecoxib in the low-
dose group are consequently well below the plasma levels
obtained in human subjects at standard celecoxib dosing. In
2002, Kisley and colleagues26 reported that most mice
treated with 1500 mg/kg chow died, and Williams and
associates27 demonstrated a serum concentration of 2.3
mol/L in mice consuming 1250 mg/kg chow without tox-
icity. On the basis of these 2 studies, a high dose (1000
mg/kg chow) was chosen to minimize toxicity and study
Figure 4. COX-2 inhibition of A549 cell proliferation in vitro. A549
proliferation was determined by using the MTS assay at indicated
doses and shows that proliferation is only impeded at higher
doses of celecoxib. Data represent 1 of 3 independent experi-
ments done in triplicate expressed as mean  standard error of
the mean. *P < .05 and **P < .01, ANOVA.mouse attrition.
1246 The Journal of Thoracic and Cardiovascular Surgery ● JunAll 3 doses of celecoxib were found to significantly
reduce total tumor volume, although intergroup differences
between treatment regimens were neither significant nor
showed a dose-dependent response. Given the existing ev-
Figure 5. A, COX-2 Western blot of treated A549 cells. IL-1 at 1
ng/mL stimulates the production of COX-2. Celecoxib treatment
does not attenuate IL-1 COX-2 production. B, COX-2 mRNA is
induced by 24 hours of IL-1 stimulation. Celecoxib treatment
might augment the mRNA response. COX-2 and -actin PCR
products were visualized on ethidium bromide gels. U, Unstimu-
lated cells; V, vehicle (1% DMSO); C10, 10 mol/L celecoxib;
IL-1b, IL-1; C50, 50 mol/L celecoxib. C, A549 PGE2 level at 24
hours. IL-1 stimulates the production of PGE2. COX-2 enzyme
activity is inhibited by 10 and 50 mol/L celecoxib. Data are
representative of 3 experiments and expressed as means 
standard error of the mean.idence, it was surprising to not find further attenuation of
e 2005
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toxicity of this compound. Absence of a dose-dependent
effect might be multifactorial, in part related to this adeno-
carcinoma cell line, A549, or the initiation of selective
COX-2 inhibition with celecoxib at the time of tumor cell
implantation. Additionally, implantation of tumor cells in
lung tissue might allow crucial stromal cell and extracellular
matrix interplay to develop; this could include tumor–
stromal cell activation of COX-2 mechanisms, where stro-
mally derived COX-2 is important for tumor growth.28
Stromally derived processes dependent on COX-2 might be
sensitive to low-dose inhibition.8,12,27
Additional in vitro studies were undertaken to further
understand an absence of a dose-dependant response in
vivo. A549 cells were studied with respect to the effect of
selective COX-2 inhibition on cell growth, proliferation,
COX-2 mRNA and protein, and the measurement of pros-
taglandin produced. A549 cells, when cultured, demonstrate
dose-dependent COX-2 inhibition of proliferation at 24
hours. At concentrations of greater than 50 mol/L cele-
coxib, proliferation as measured by MTS was decreased,
and at concentrations of 100 mol/L, cell death was ob-
served (Figure 4). An important observation from this ex-
periment is that treatment with 10 mol/L or less for 24
hours had no detrimental effect on cell proliferation. Despite
this lack of effect in cultured A549 cells, we found that
celecoxib strongly attenuated the growth of A549 tumors in
vivo when the plasma concentration of celecoxib was ap-
proximately 1 mol/L. Epidemiologic studies in bladder
and prostrate cancer of patients receiving long-term
NSAIDs suggest an antitumor effect at doses sufficient to
suppress inflammatory pain.29,30 The more recent data of
chronic low-dose aspirin users further suggest that COX
enzyme modulation has a chronic protective role against
NSCLC.31,32
A549 cells in standard culture conditions have low basal
levels of COX-2 mRNA and protein. It has been shown that
the presence of inflammatory cytokines increases the pro-
duction of COX-2 mRNA and protein (Figure 5). This
response occurred in A549 cells on exposure to IL-1, in
which an increase in COX-2 protein and PGE2 was mea-
sured after the stimulus (Figure 5). Similarly, the in vivo
tumors have increased COX-2 protein, as shown with im-
munohistochemistry (Figure 3), and this appears to be great-
est at the tumor–stromal cell interface. When celecoxib at
doses of as low as 10 mol/L is added to the IL-1–
stimulated cells, production of PGE2 returned to baseline
levels. This occurred despite a subjective increase in COX-2
protein levels after cytokine stimulation (Figure 5). The
efficiency of the COX-2 inhibitor to block the production of
prostanoids is shown by the low levels of PGE2 produced by
the A549 cells when exposed to celecoxib, even after stim-
ulation to transcribe very high quantities of COX-2 protein.
The Journal of ThoracicBy using PGE2 production as a surrogate for COX-2 en-
zyme activity, there is an expectation in vitro that a greater
effect on cell proliferation would be observed at low con-
centrations in both the cell growth and MTS assays. The fact
that there is no significant change in cell viability observed
with lower concentrations of celecoxib would seem to
indicate that cell death in vitro occurs through COX-2–
independent mechanisms and only at very high concentra-
tions. These studies do not address the issue of whether
celecoxib attenuates tumor growth in vivo through either
COX-2–dependent or COX-2–independent mechanisms.
However, in this orthotopic animal model, doses sufficient
to block enzyme activity support, at least in part, a COX-2–
dependent mechanism.
In summary, inhibition of COX-2 with low-dose cele-
coxib restricted the growth of a lung adenocarcinoma cell
line in this orthotopic mouse model. Two higher doses of
celecoxib afforded no additional benefit and might be
unnecessary. This study illustrates that caution must be
used when attempting to extrapolate in vitro results to the
context of in vivo models and human subjects, recogniz-
ing that cell culture plasma levels of a compound often
far exceed what can be obtained in patients. Despite this
difficulty, chronic therapy with low-dose COX-2 inhibi-
tion has the potential to interfere with disease progression
in patients with NSCLC.
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Dr Richard Whyte (Stanford, Calif). I thought that this was a
very good article that was an elegant combination of both the in
vivo and in vitro model of looking at COX-2 inhibition in a lung
cancer model. Although not particularly mechanistic in its con-
struction, I think that in the beginning part of your presentation,
you did talk about the potential mechanisms of action of COX-2
inhibition, namely that of inhibition of apoptosis and angiogenesis,
as well as metastasis. I would urge anybody who is interested in
reading more about this to go to an article that this group published
in The Annals of Thoracic Surgery last year, a review article that
summarizes these mechanisms elegantly, and it is well worth the
read if you are interested in this.
I have 2 questions for you. The first is whether you could
explain a bit more about the disparity in terms of the in vivo–in
vitro models in terms of dose dependency. In the in vivo model
you saw a decrease in growth of tumors at one dose but not at
higher doses, whereas in the in vitro model there was more of an
ongoing correlation, and I wonder why this is the case. In the in
vitro model you have gradation of exposure to celecoxib. In the in
vivo model you put it in the food, and I do not know whether you
have any correlations between how much food these animals
ingested, their plasma levels. In some models with animals, you
give them a certain amount of this drug every day, whereas I do not
know whether you know how much of the drug they actually got
and whether that sort of confounded things slightly.
The other question I have is a more global question in terms of
the epidemiology of this. It gets to the fact that some of these
COX-2 inhibitors or COX inhibitors—whether it be aspirin or
Celebrex or whatever, they are in such widespread use now—I
wonder how it is going to be possible to determine any effect of an
epidemiologic basis of these because essentially everybody takes,
or at least many people take, some sort of a low-dose COX
inhibitor, whether it is an aspirin a day to minimize heart attacks
or whether it is Celebrex or something like that after, say, a
shoulder injury while playing tennis. That sort of ubiquitous use of
these drugs would make it very hard to do a study on this. I am
wondering whether we should put our patients with lung cancer
now on an aspirin a day just as we do to prevent heart attacks.
Dr Sievers. Thank you very much, Dr Whyte, for your kind
words. I will try to answer your questions.
We like to caution against comparing both in vitro and in vivo
data, despite the fact that we draw the parallels in this study. The
main point of pointing out both of those drug treatments in serum
levels in a dish and serum levels in the animal in the same
presentation in the same article was to counteract some of the
evidence that has been put out by some of our basic science
colleagues in which antiapoptotic effects were demonstrated at
celecoxib concentrations that are superphysiologic. Therefore al-
though that is a problem, we wanted to highlight that we can still
inhibit the tumor progression in this in vivo model at doses that are
very low.
As far as how much our mice consume, this was a drug that was
in the chow as opposed to gavage feeding, but over many exper-
iments with many animals, we were able to keep track of exactly
how much they ate, and our low-dose group did have blood levels
that correlated with our previous experiments and with the litera-
ture.
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TSAs far as all our patients taking the odd aspirin or Advil, that is
definitely a problem, as our chemotherapy colleagues are finding
out in these new prospective trials of combined therapy by adding
celecoxib to standard chemotherapy regimens, but to note in the
epidemiologic evidence presented with aspirin and breast cancer
recently, they defined high-dose or high exposure of aspirin as
taking more than 7 full-strength, 325-mg aspirins a week to count
as achieving reduced risk.
Should we be taking NSAIDs to prevent cancer? Judging from
our available data, we probably think that is a good idea, but again,
long-term studies do need to be performed.
Dr Douglas Wood (Seattle, Wash). I offer my congratulations
to you and Ross Bremner’s laboratory. You are doing great work.
I have a couple of questions.
First, do you have to give little doses of H2 antagonist to your
mice to keep them from having gastric ulcers? On a more serious
basis, with the new information that adjuvant chemotherapy now
seems to be appropriate for even early stage resected lung cancer,
The Journal of Thoracicwill that potentially negate the potential benefit of COX-2 antag-
onists, or would this be given in addition to adjuvant chemother-
apy? Are we at the stage where ought to go to The American
College of Surgeons Oncology Group (ACOSOG) and propose a
clinical trial on the basis of your work?
Dr Sievers. Thank you, Dr Wood. No, our mice did not have
gastric ulcers. We did in fact look for them, and none were found
in any of our experiments here or previously mentioned.
As far as combined chemotherapy or the question of adding
celecoxib regimens or COX-2 inhibitory therapy to standard
regimens, those are going to happen anyway. Our patients are
still taking COX-2 inhibitors whether we want them to or not,
and I do not think that the COX-2 inhibition by itself is going
to negate any chemotherapy that is happening. In fact, we know
this from some radiotherapy trials, as well as some chemother-
apy trials both in animals and in early stages in human subjects.
In arguments it does seem to potentiate the effect of chemo-
therapy.
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